
Bausch Health Cos Inc. (NYSE:BHC – Free Report) – Stock analysts at Zacks Research raised their FY2026 earnings estimates for shares of Bausch Health Cos in a research note issued to investors on Wednesday, November 18th. Zacks Research analyst Team now expects that the company will earn $4.98 per share for the year, up from their prior forecast of $4.24. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.53 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q3 2028 earnings at $0.72 EPS and FY2028 earnings at $3.03 EPS.
Bausch Health Cos (NYSE:BHC – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.52. Bausch Health Cos had a negative net margin of 7.57% and a negative return on equity of 401.73%. The company had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.72 billion.
Other equities analysts have also recently issued reports about the company. Royal Bank Of Canada upped their price objective on Bausch Health Cos from $9.00 to $10.00 and gave the stock a “sector perform” rating in a report on Thursday, October 29th. Barclays raised their price objective on Bausch Health Cos from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Wednesday, November 11th. Weiss Ratings restated a “sell (d)” rating on shares of Bausch Health Cos in a research report on Thursday, October 29th. Jefferies Financial Group upped their target price on Bausch Health Cos from $6.50 to $8.00 and gave the stock a “hold” rating in a research note on Thursday, October 29th. Finally, Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bausch Health Cos has a consensus rating of “Reduce” and an average target price of $8.75.
Check Out Our Latest Analysis on Bausch Health Cos
Bausch Health Cos Stock Down 1.8%
NYSE BHC opened at $8.57 on Friday. The stock’s 50-day simple moving average is $6.75 and its two-hundred day simple moving average is $5.86. Bausch Health Cos has a twelve month low of $4.33 and a twelve month high of $9.04. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -3.74 and a beta of 0.30.
Hedge Funds Weigh In On Bausch Health Cos
A number of hedge funds have recently modified their holdings of the company. Paulson & CO. Inc. bought a new stake in shares of Bausch Health Cos in the second quarter worth about $361,151,000. Royal Bank of Canada lifted its holdings in Bausch Health Cos by 24.9% in the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock worth $61,362,000 after buying an additional 2,262,894 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Bausch Health Cos by 24.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 7,748,378 shares of the company’s stock worth $45,173,000 after buying an additional 1,523,247 shares during the last quarter. MFN Partners Management LP bought a new position in shares of Bausch Health Cos during the second quarter valued at approximately $29,580,000. Finally, Dimensional Fund Advisors LP lifted its stake in Bausch Health Cos by 10.8% in the first quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock worth $19,456,000 after acquiring an additional 350,823 shares during the period. Hedge funds and other institutional investors own 78.65% of the company’s stock.
Key Stories Impacting Bausch Health Cos
Here are a few of the latest stories about BHC:
- Positive Sentiment: Zacks Research raised its FY2027 EPS estimate to $3.89 from $3.85 and increased estimates for several quarters, including Q4 2026 and Q1–Q2 2027. The revisions suggest slightly improved analyst expectations. MarketBeat analyst estimate updates
- Neutral Sentiment: Zacks Research maintained a Hold rating, indicating the estimate changes did not come with a more bullish recommendation. MarketBeat analyst estimate updates
- Negative Sentiment: Zacks lowered its Q3 2027 EPS forecast to $1.05 from $1.07, a small counterpoint to the other estimate increases. MarketBeat analyst estimate updates
Bausch Health Cos Company Profile
Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics. Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.
Featured Articles
- Five stocks we like better than Bausch Health Cos
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.
